Journal of Jilin University(Medicine Edition) ›› 2023, Vol. 49 ›› Issue (6): 1599-1603.doi: 10.13481/j.1671-587X.20230625

• Clinical medicine • Previous Articles     Next Articles

Pustular psoriasis treated with secukinumab during pregency: A case report and literature review

Qinghua PING,Wenjing ZHU,Jianxin XIA()   

  1. Department of Dermatology,Second Hospital,Jilin University,Changchun 130041,China
  • Received:2022-11-27 Online:2023-11-28 Published:2023-12-22
  • Contact: Jianxin XIA E-mail:911469806@qq.com

Abstract:

Objective To discuss the safety of secukinumab treatment during pregnancy,and to provide the reference for the treatment of psoriasis patients during pregnancy. Methods A case of pustular psoriasis safely treated with secukinumab during pregnancy was collected and combined with the relevant literature review, the safety of secukinumab treatment for the psoriasis during pregnancy was analyzed. Results The patient was a 28-year-old woman with a body weight of 50 kg. The patient had been experiencing generalized erythema and scales for 5 years, which worsened with pustules for 1 year.The dermatology examination results showed large patches of erythema, silver-white scales and small pustules on the skin of the patient, no changes in the nails, and was not accompanied by the joint symptoms. The patient was diagnosed as generalized pustular psoriasis. After being treated with secukinumab for 2 months, the psoriasis area and severity index (PASI) was 0; the patient unexpectedly became pregnant after treated for 10 months.Secukinumab was continued throughout the pregnancy until 20 d before delivery, and the patient gave birth to a healthy full-term female baby with the body weight of 3.6 kg. Conclusion Secukinumab can be used as a therapeutic option for the patients with psoriasis during pregnancy, but more clinical cases and drug research are needed to evaluate its safety during pregnancy.

Key words: Secukinumab, Pregnancy, Psoriasis, Biologics, Case report

CLC Number: 

  • R758.63